IP Library Granted Patent US 11,944,725
Granted Patent B2
US 11,944,725 · App. 17/255,879 · Granted Apr 2, 2024

Pro-healing, pro-regenerative nanofibrous coating for medical implants

Inventors: Parnaz Boodagh (Boulder, CO); Wei Tan (Broomfield, CO); Michael Floren (Broomfield, CO)
Assignee: The Regents of the University of Colorado, A Body Corporate
A61L31/10A61L31/16A61L27/507A61L2300/416A61L2300/42A61L2300/604A61L2300/606A61L2400/12A61L2420/02A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,944,725
App. No.
17/255,879
Granted
Apr 2, 2024
Kind
B2
Abstract

The present invention relates to a medical implant, and more particularly, to a vascular implant having a dual coating structure for preventing in-stent restenosis and thrombosis. In one embodiment, the invention contemplates a vascular stent with a coating comprising a hydrophobic, degradable core with a coaxial sheath comprising at least one polyethylene-glycol derivative. In one embodiment, the at least one polyethylene-glycol derivative comprises polyethylene-glycol dimethacrylate.

Claims (15)

1. A medical implant with a coating comprising a hydrophobic, degradable core with a coaxial sheath comprising at least one polyethylene-glycol derivative,

wherein said hydrophobic, degradable core comprises a poly L-lactide acid (PLLA) core,

wherein said at least one polyethylene-glycol derivative of said coaxial sheath comprises polyethylene-glycol dimethacrylate (PEGDMA),

wherein said coating comprises a hybrid fiber coating,

wherein said medical implant comprises a vascular stent.

2. The medical implant of claim 1 , wherein said coating further comprises a controlled release agent.

3. The medical implant of claim 1 , wherein said coating further comprises a therapeutic agent.

4. The medical implant of claim 3 , wherein said therapeutic agent comprises an anti-proliferation agent.

5. The medical implant of claim 1 , wherein said hydrophobic, degradable core provides controlled drug release.

6. The medical implant of claim 1 , wherein said sheath integrates a surface signaling mechanism.

7. The medical implant of claim 6 , wherein said surface signaling mechanism is configured to simultaneously aid in regeneration.

8. The medical implant of claim 1 , wherein said coating further comprises sub-millimeter scale fibers.

9. The medical implant of claim 8 , wherein said sub-millimeter scale fibers provide a uniform surface.

10. The medical implant of claim 1 , wherein said coating has no delamination.

11. The medical implant of claim 1 , wherein said coating has an elastic modulus ranging from 100 to 1000 kPa.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: BOODAGH, PARNAZ; TAN, WEI; FLOREN, MICHAEL
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 055931/0785 →
CONFIRMATORY LICENSE Recorded Jan 7, 2021
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054916/0817 →
Continuity (2)
Provisional Application 62692209 · Jun 29, 2018
Related Publication 20210260256A1 · Aug 26, 2021